Applicable to validated and difficult novel targets, such as GPCRs and ion channels Immunogen "agnostic"

  • Pure proteins, protein preparations, peptides, whole cells, DNA
  • Pure immunogen not required

>200 different recombinantly expressed monoclonals covering an array of affinities and epitopes arise per project

  • Leads and backups immediately available
  • No further affinity optimization of initial hits required

Screen for synergies for combination therapies, including bi-specifics